The population with type 2 DM (DM2) is highly heterogeneous, representing an important challenge for healthcare professionals. The therapeutic choice should be individualized, considering the functional status, frailty, the occurrence of comorbidities, and the preferences of patients and their caregivers. New evidence on the cardiovascular and renal protection of specific therapeutic groups and on the usefulness of new technologies for DM2 management, among other aspects, warrant an update of the consensus document on the DM2 in the elderly that was published in 2018.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rceng.2022.03.005 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!